Zimmer Biomet Holdings, Inc.

• ZBH Stock Price 24h change: +1.52%. From 92.85 USD to 94.08 USD. The price rebounded slightly following mixed technical sentiment and earlier guidance adjustments, as investors monitored the company's presentation at the J.P. Morgan Healthcare Conference.• From a technical perspective, the stock is currently in a "neutral to bearish consolidation" phase. The 14-day RSI stands at 46.7, signaling neutral momentum, while the stock remains below its 200-day simple moving average of 96.99, indicating a long-term bearish trend. Short-term moving averages (MA5, MA10) show a slight sell bias, though the stock is attempting to stabilize near its 50-day MA of 93.19.• Zimmer Biomet presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, highlighting its multi-year transformation, supply chain remediation, and a goal of <1 day backorders.• On January 12, the company announced the formal resignation of executive officer Mark Bezjak, effective January 16, 2026, as he pursues other business opportunities.• Analysts from Bernstein and Evercore ISI recently updated their views, with Evercore shifting to an "Outperform" rating, citing a valuation gap as the stock trades at a significant discount to its estimated intrinsic value.• Medtronic announced plans to separate its diabetes business into a standalone publicly traded company by the end of 2026, reflecting a broader trend of portfolio simplification in the medtech sector.• Johnson & Johnson filed a De Novo submission for its Ottava surgical robot on January 7, intensifying competition in the robotic-assisted surgery space where Zimmer Biomet also operates.

• ZBH Stock Price 24h change: -1.31%. From 94.08 USD to 92.85 USD. The decline was influenced by broader market caution and analyst concerns over "execution sticking points" despite long-term optimism regarding its robotic surgery growth.
• From a technical perspective, the stock is in a "short-term bearish consolidation": ZBH is currently trading below its 50-day (93.19) and 200-day (96.99) moving averages, with a Relative Strength Index (RSI) of 43.56 signaling neutral momentum. Technical indicators lean toward a "Sell" in the short term as the price tests support near $88.65.
• Zimmer Biomet announced the formal resignation of executive Mark Bezjak effective January 16, 2026; while previously disclosed, the formalization adds to recent executive shifts following his transition out of the role in mid-2025.
• Analysts at Evercore ISI recently upgraded ZBH to "Outperform" with a $120 target, citing potential turnaround success, while other firms like Citigroup lowered targets to $94 due to concerns over knee segment competition and operating margins.
• The medical device sector is facing a massive wave of contract renegotiations in early 2026; rising supply chain costs and new trade tariffs are forcing manufacturers to adjust pricing strategies by up to 15%.
• AI integration in surgical robotics is accelerating, with companies like EndoQuest and Natera partnering with NVIDIA (Jan 12) to integrate Blackwell-powered platforms for next-generation precision medicine and visualization.